These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35543739)

  • 1. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Aug; 395(8):867-885. PubMed ID: 35543739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1619-1632. PubMed ID: 36951997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2949-2970. PubMed ID: 38530400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020.
    Kayki-Mutlu G; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2021 May; 394(5):839-852. PubMed ID: 33864098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
    Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
    Benjamin DJ; Xu A; Lythgoe MP; Prasad V
    JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.
    Gupta R; Morten CJ; Zhu AY; Ramachandran R; Shah ND; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221096. PubMed ID: 35977259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review.
    Sangwan K; Sharma V; Goyal PK
    Curr Mol Med; 2024; 24(6):734-750. PubMed ID: 37350009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions.
    Brown DG; Wobst HJ
    J Med Chem; 2021 Mar; 64(5):2312-2338. PubMed ID: 33617254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
    Monge AN; Sigelman DW; Temple RJ; Chahal HS
    JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.
    Gu J; Wu Q; Zhang Q; You Q; Wang L
    Eur J Med Chem; 2022 Dec; 243():114742. PubMed ID: 36155354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2022 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2023 Aug; 28(8):103622. PubMed ID: 37201782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.